Hearn Jay Cho - Concepedia

Author

Hearn Jay Cho

Icahn School of Medicine at Mount Sinai ORCID

Also Known As

Cho, Hearn Jay, HEARN JAY CHO, Hearn Jay Cho, Hearn J Cho, Hearn J. Cho, Hearn Jay Cho, Kenneth C. Anderson, Wayne Harris

324

Publications

5.9K

Citations

H-Index

Concepts

All Affiliations

Icahn School of Medicine at Mount Sinai Cornell University Tisch Hospital Tisch Cancer Institute Multiple Myeloma Research Foundation

About

Hearn Jay Cho is an author at Icahn School of Medicine at Mount Sinai specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	21	2.9K
2	Health Sciences	5	5	119
3	Engineering	2	2	59
4	Allergy	1	1	1.9K
5	Biochemistry	1	1	1.9K

Hearn Jay Cho

Publications

5.1K

Citations

H-Index

Page 1

	Year	Citations
Cloning and Characterization of Inducible Nitric Oxide Synthase from Mouse Macrophages Q W Xie, Hearn Jay Cho, Jimmy Calaycay, Science Nitric OxideImmunologyImmunotherapyCellular PhysiologyOxidative Stress	1992	1.9K
Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism Hearn Jay Cho, Kenji Takabayashi, Pei-Ming Cheng, Nature Biotechnology VaccinationImmunostimulatory Dna-based VaccinesT-helper Cell-independent MechanismCytotoxic Lymphocyte ActivityImmunology	2000	259
Rituximab in the treatment of acquired factor VIII inhibitors Adrian Wiestner, Hearn Jay Cho, Adam S. Asch, Blood	2002	214
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Rubén Niesvizky, David Jayabalan, Paul J. Christos, Blood	2007	182
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation Achim A. Jungbluth, Scott Ely, Maurizio DiLiberto, Blood	2005	180
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma Rachid Baz, Thomas G. Martin, Hui‐Yi Lin, Blood	2016	157
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward Bo Wang, Oliver Van Oekelen, Tarek H. Mouhieddine, Journal of Hematology & Oncology	2020	141
Mutually Exclusive Cyclin-Dependent Kinase 4/Cyclin D1 and Cyclin-Dependent Kinase 6/Cyclin D2 Pairing Inactivates Retinoblastoma Protein and Promotes Cell Cycle Dysregulation in Multiple Myeloma Scott Ely, Maurizio Di Liberto, Rubén Niesvizky, Cancer Research	2005	113
IFN-αβ Promote Priming of Antigen-Specific CD8+ and CD4+ T Lymphocytes by Immunostimulatory DNA-Based Vaccines Hearn Jay Cho, Tomoko Hayashi, Sandip K. Datta, The Journal of Immunology	2002	112
Immunostimulatory DNA Is a Potent Mucosal Adjuvant Anthony A. Horner, Arash Ronaghy, Pei-Ming Cheng, Cellular Immunology Potent Mucosal AdjuvantMucosal VaccinationAutoimmune DiseaseMucosal ImmunologyMedicine	1998	101

Page 1